Study analysis · Atherosclerosis · 2025
Your blood test might be predicting your next heart attack — even if you feel fine.
If your blood has more than 2 mg/L of this inflammation marker after a stent, you’re at higher risk for a heart attack, stroke, or death within a year.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at people who had a heart procedure and noticed that those with higher levels of a certain blood marker had more heart problems later. But it didn't change anything on purpose—it just watched what happened—so we can't say the marker caused the problems, just that they often happened together.
What’s the bottom line?
Doctors checked a blood marker called hsCRP in patients who got stents to see if it could predict heart attacks or strokes within a year.
How strong is this study?
The study looked at a lot of people, which is good, but it only used old records and didn't control for things like diet or other illnesses. That means we can't be super sure the results are totally reliable—like trying to guess why someone got sick just by looking at their shoe size.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
38 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=10811)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is a retrospective cohort study with no explicit randomization, blinding, or control group described. Association does not imply causation, and unmeasured confounders may influence results.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding information were disclosed in the provided text.
The study is retrospective and conducted at a single academic hospital (Mount Sinai), but no funding sources, author affiliations with industry, or conflict of interest disclosures were provided. Absence of disclosure does not imply absence of conflict, but based on available text, no evidence of bias or industry influence was found.
Key takeaways
- 01
Patients with hsCRP above 3 mg/L had a 4.9% chance of heart attack/stroke/death in a year; those below 2 mg/L had 2.6%.
- 02
Those between 2 and 3 mg/L had a 44% higher risk than those below 2 mg/L.
- 03
Even moderate inflammation (2–3 mg/L) raises heart risks after stent surgery — so it’s not just very high levels that matter.
Surprising findings
- Patients with hsCRP between 2–3 mg/L had a statistically significant 44% higher risk of MACCE compared to those below 2 mg/L.Many assume only hsCRP >3 mg/L is clinically meaningful — but this shows even the ‘gray zone’ carries real risk.
Practical takeaways
If you’ve had a stent, ask your doctor for your hsCRP level — if it’s above 2 mg/L, discuss whether you need more aggressive prevention.
This study was retrospective and didn’t control for lifestyle, medications, or other risk factors — so it shows correlation, not causation.
low confidenceWhy this study matters
Moderate Inflammation = Higher Risk
Patients with hsCRP levels between 2 and 3 mg/L had a 44% higher risk of heart attack, stroke, or death within one year compared to those below 2 mg/L. This means even ‘mild’ inflammation isn’t harmless after stent surgery.
Most people think only very high inflammation is dangerous — but this shows even borderline levels matter after heart procedures.
2 vs. 3 mg/L: Which Threshold Wins?
The study found that both 2 mg/L and 3 mg/L thresholds predicted heart risks equally well using ROC analysis. Neither was clearly better at identifying who’d have a bad outcome.
Doctors often debate which cutoff to use — this study says it doesn’t matter much. That’s a big deal for clinical guidelines.
One in 20 Patients at Risk
Patients with hsCRP above 3 mg/L had a 4.9% chance of MACCE (death, heart attack, stroke) in one year — compared to just 2.6% for those below 2 mg/L.
That’s nearly double the risk — and it’s based on a simple, common blood test most people already get.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Doctors checked a blood marker called hsCRP in patients who got stents to see if it could predict heart attacks or strokes within a year.
Research results
Patients with hsCRP above 3 mg/L had a 4.9% chance of heart attack/stroke/death in a year; those below 2 mg/L had 2.6%. Those between 2 and 3 mg/L had a 44% higher risk than those below 2 mg/L.
What this means - more context
Even moderate inflammation (2–3 mg/L) raises heart risks after stent surgery — so it’s not just very high levels that matter.
To evaluate whether different hsCRP thresholds (2 mg/L and 3 mg/L) better predict one-year major adverse cardiac and cerebrovascular events (MACCE) in patients with coronary artery disease undergoing PCI.
In 10,811 patients undergoing PCI, elevated baseline hsCRP levels (>2 mg/L and >3 mg/L) were associated with higher rates of MACCE. Patients with hsCRP 2–3 mg/L had a 44% higher risk of MACCE than those <2 mg/L. Both thresholds showed similar predictive ability by ROC analysis.
Methods Used
Retrospective analysis of patients undergoing PCI from 2012 to 2022 at Mount Sinai Hospital; patients stratified by baseline hsCRP levels (<2 mg/L, 2–3 mg/L, >3 mg/L); primary endpoint was MACCE (all-cause mortality, myocardial infarction, stroke).
Main Finding
MACCE rates were 4.9% for hsCRP >3 mg/L vs. 2.6% for <2 mg/L (p<0.001); 4.4% for hsCRP ≥2 mg/L vs. 2.4% for <2 mg/L (p<0.001); hazard ratio for MACCE in 2–3 mg/L group vs. <2 mg/L was 1.44 (95% CI 1.03–2.00; p=0.032); ROC curves showed similar predictive ability for both thresholds.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Retrospective design with unknown confounding controls
- •No information on medication use, lifestyle, or other risk factors adjusted for
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Patients with hsCRP between 2–3 mg/L had a statistically significant 44% higher risk of MACCE compared to those below 2 mg/L.
Many assume only hsCRP >3 mg/L is clinically meaningful — but this shows even the ‘gray zone’ carries real risk.
Practical Takeaways
If you’ve had a stent, ask your doctor for your hsCRP level — if it’s above 2 mg/L, discuss whether you need more aggressive prevention.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at people who had a heart procedure and noticed that those with higher levels of a certain blood marker had more heart problems later. But it didn't change anything on purpose—it just watched what happened—so we can't say the marker caused the problems, just that they often happened together.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Large sample size (n=10,811)
- Clear primary endpoint (MACCE)
- Use of established hsCRP thresholds
Weaknesses
- Retrospective design
- No explicit randomization or control group
- Blinding status unknown
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Doctors checked a blood marker called hsCRP in patients who got stents to see if it could predict heart attacks or strokes within a year.
Research results
Patients with hsCRP above 3 mg/L had a 4.9% chance of heart attack/stroke/death in a year; those below 2 mg/L had 2.6%. Those between 2 and 3 mg/L had a 44% higher risk than those below 2 mg/L.
What this means - more context
Even moderate inflammation (2–3 mg/L) raises heart risks after stent surgery — so it’s not just very high levels that matter.
To evaluate whether different hsCRP thresholds (2 mg/L and 3 mg/L) better predict one-year major adverse cardiac and cerebrovascular events (MACCE) in patients with coronary artery disease undergoing PCI.
In 10,811 patients undergoing PCI, elevated baseline hsCRP levels (>2 mg/L and >3 mg/L) were associated with higher rates of MACCE. Patients with hsCRP 2–3 mg/L had a 44% higher risk of MACCE than those <2 mg/L. Both thresholds showed similar predictive ability by ROC analysis.
Methods Used
Retrospective analysis of patients undergoing PCI from 2012 to 2022 at Mount Sinai Hospital; patients stratified by baseline hsCRP levels (<2 mg/L, 2–3 mg/L, >3 mg/L); primary endpoint was MACCE (all-cause mortality, myocardial infarction, stroke).
Main Finding
MACCE rates were 4.9% for hsCRP >3 mg/L vs. 2.6% for <2 mg/L (p<0.001); 4.4% for hsCRP ≥2 mg/L vs. 2.4% for <2 mg/L (p<0.001); hazard ratio for MACCE in 2–3 mg/L group vs. <2 mg/L was 1.44 (95% CI 1.03–2.00; p=0.032); ROC curves showed similar predictive ability for both thresholds.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Retrospective design with unknown confounding controls
- •No information on medication use, lifestyle, or other risk factors adjusted for
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Patients with hsCRP between 2–3 mg/L had a statistically significant 44% higher risk of MACCE compared to those below 2 mg/L.
Many assume only hsCRP >3 mg/L is clinically meaningful — but this shows even the ‘gray zone’ carries real risk.
Practical Takeaways
If you’ve had a stent, ask your doctor for your hsCRP level — if it’s above 2 mg/L, discuss whether you need more aggressive prevention.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at people who had a heart procedure and noticed that those with higher levels of a certain blood marker had more heart problems later. But it didn't change anything on purpose—it just watched what happened—so we can't say the marker caused the problems, just that they often happened together.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Large sample size (n=10,811)
- Clear primary endpoint (MACCE)
- Use of established hsCRP thresholds
Weaknesses
- Retrospective design
- No explicit randomization or control group
- Blinding status unknown
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study looked at a lot of people, which is good, but it only used old records and didn't control for things like diet or other illnesses. That means we can't be super sure the results are totally reliable—like trying to guess why someone got sick just by looking at their shoe size.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
38 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=10811)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is a retrospective cohort study with no explicit randomization, blinding, or control group described. Association does not imply causation, and unmeasured confounders may influence results.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding information were disclosed in the provided text.
The study is retrospective and conducted at a single academic hospital (Mount Sinai), but no funding sources, author affiliations with industry, or conflict of interest disclosures were provided. Absence of disclosure does not imply absence of conflict, but based on available text, no evidence of bias or industry influence was found.